Horizon Therapeutics plc — Cyborg Score 7/10

Strong
Rare disease biopharmaceuticals

Strategic Profile

Horizon positioned itself as a high-growth biotech company specializing in orphan and rare disease therapeutics, with strong commercial execution in immunomodulation. The company demonstrated consistent double-digit revenue growth and operated manufacturing facilities in Ireland, reflecting a regional presence in biopharma development.

Cyborg Score Rationale

Pre-acquisition, Horizon demonstrated strong commercial performance with rapid uptake of key medicines, consistent growth in core markets, and an expanding pipeline. However, this evaluation is historical as the company was acquired by Amgen in December 2023.

Top Insights

  • TEPEZZA launched with exceptional rapid uptake in thyroid eye disease market, significantly exceeding initial expectations
  • KRYSTEXXA experienced 46% year-over-year sales growth driven by immunomodulation strategy success
  • UPLIZNA generated 76% year-over-year sales growth with Phase 3 programs in IgG4-RD and myasthenia gravis
  • Company acquired by Amgen (December 2023) and delisted from NASDAQ

Named Competitors

  • Regeneron Pharmaceuticals — Biopharmaceutical company developing specialty medicines
  • Ultragenyx Pharmaceutical — Biopharmaceutical company focused on rare and ultra-rare genetic diseases
  • Sesen Bio — Rare disease biopharmaceutical company specializing in immunotherapy
  • Agios Pharmaceuticals — Biopharmaceutical company developing therapies for rare metabolic disorders
  • Athena Therapeutics — Rare disease focused biopharmaceutical company in neurological and genetic disorders

Recent Developments

  • (December 2023) Acquired by Amgen, delisted from NASDAQ with final trade on December 8, 2023
  • (Q2 2023) Reported double-digit year-over-year growth and mid-teens sequential growth
  • (2021) Acquired Viela Bio to expand development pipeline with four candidates in nine programs

Open the full interactive Horizon Therapeutics plc report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →